Evaluation of a new transdermal testosterone dosage used for 60 days prior to controlled ovarian stimulation in poor responders: preliminary results

Objectives: Studies suggest a beneficial effect of transdermal testosterone (TT) used prior to controlled ovarian stimulation (COS) on reproductive outcomes in poor responders. Our aim was evaluate the adverse effects and serum concentrations testosterone, sex hormone-binding globulin (SHBG), estradiol, following new TT dosage associated with combined oral contraceptive (COC) before COS Methods: Pilot case-control study which each patient her own case-control. Women response fulfilling Bologna Criteria were recruited submitted (Control Cycle - CC) perform ICSI. Those who did not become pregnant subjected another previous use (25 mg/48 hours, for 60 days), COC (Testosterone Cycle-TC). Blood samples taken at beginning first (D1); day oocyte retrieval (D2), (D3); days after Testo-COC usage (D4); second (D5). Adverse total free SHBG analyzed. Results: Six women concluded both cycles. Testosterone higher D4 than D1 (p=0.009, p=0.041) D3 (p=0.010, p=0.031). (p=0.028). Estradiol D2 (p<0.001) D5 (p=0.001) (p=0.002). Mild observed. Conclusion: The caused only mild resulted significantly basal conditions.